NCT01695044View on ClinicalTrials.gov

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

February 28, 2015

Conditions
Prostate Cancer
Interventions
DRUG

PSMA ADC

PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.

Trial Locations (36)

10065

New York

11042

Lake Success

11794

Stony Brook

14642

Rochester

15232

Pittsburgh

20850

Rockville

21201

Baltimore

21205

Baltimore

23502

Norfolk

27607

Raleigh

28078

Huntersville

28109

Ann Arbor

29572

Myrtle Beach

29605

Greenville

34952

Port Saint Lucie

35205

Birmingham

38120

Memphis

44195

Cleveland

55905

Rochester

66205

Fairway

68130

Omaha

70115

New Orleans

75390

Dallas

80218

Denver

85724

Tucson

89169

Las Vegas

90024

Los Angeles

91505

Burbank

92024

Encinitas

92123

San Diego

96819

Honolulu

98101

Seattle

06520

New Haven

06856

Norwalk

02111

Boston

02906

Providence

All Listed Sponsors
lead

Progenics Pharmaceuticals, Inc.

INDUSTRY

NCT01695044 - A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter